
Genmab’s Executive VP and CFO to retire in 2020
pharmafile | October 31, 2019 | News story | Research and Development | Genmab, appointment, pharma
David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the role next year, with a proposed leaving date of 29 February 2020.
Eatwell has been with the company for 11 years, joining in 2008 as its Chief Financial Officer. He will be succeeded by Anthony Pagano, currently Senior Vice President Finance and Corporate Development at the company, who originally joined in 2007 and was promoted to Senior Vice President in 2011.
Eatwell’s exit date of February allows him to stay in the role until his responsibilities can be safely transitioned over to Pagano.
“David has been instrumental in helping build Genmab into the antibody innovation powerhouse that it is today,” commented Dr Jan van de Winkel, Chief Executive Officer of Genmab. “With David’s leadership and financial stewardship, we were able to weather some challenging years and enter transformative collaboration agreements with Janssen, GSK and Novartis. On behalf of the Genmab team, I wish David and his family the very best for the future.”
The company also revealed alongside the announcement that it will look to introduce a fourth position for an Executive Vice President and Chief Operating Officer, with a management remit covering commercial, business development and information technology functions at the company.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






